ReviewCurrent opinion in immunology2016
Immunosurveillance and immunotherapy of tumors by innate immune cells.
Review in Current opinion in immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 98 citations in OpenAlex.
- LMO1 expression in neuroblastoma cells reprograms tumor-associated macrophages to promote metastasis.iScience · 2026Article
- Alpha-Fetoprotein Stimulates Cleavage of Membranal MICA/B on Liver Cancer Cell Lead to Escape Immune Surveillance of Natural Killer Cells.Journal of cellular and molecular medicine · 2026Article
- Novel perspectives on extracellular vesicles in autoimmune diseases: immunogenicity, inflammation, and immune surveillance.The Journal of clinical investigation · 2026Review
- Leveraging the heterogeneity of the NK cell repertoire for the development of immunotherapies for acute leukemia.Journal of translational medicine · 2025Review
- HypoxamiRs in pancreatic cancer: master regulators of the hypoxic tumor microenvironment.Cell biology and toxicology · 2025Review
- Intravesical VSVd51-GM-CSF virotherapy is superior to BCG in treating bladder cancer in preclinical and translational models.Molecular therapy. Oncology · 2025Article
- Molecular Interactions Between NK Cells and Acute Leukemic Cells: KIR2DL5 Drastically Limits NK Cell Responses.Journal of clinical immunology · 2025Article
- Epithelial cell competition is promoted by signaling from immune cells.Nature communications · 2025Article
- High Level of CD8Cells · 2024Article
- Tumor microenvironment-responsive DNA-based nanomedicine triggers innate sensing for enhanced immunotherapy.Journal of nanobiotechnology · 2023Article
- Allogeneic natural killer cell therapy.Blood · 2023Review
- Review
- Hypoxia mediates immune escape of pancreatic cancer cells by affecting miR-1275/AXIN2 in natural killer cells.Frontiers in immunology · 2023Article
- Glomerular diseases after immune checkpoint inhibitors use: What do We know so far?Renal failure · 2022Article
- Comorbidities involving parasitic diseases: A look at the benefits and complications.Experimental biology and medicine (Maywood, N.J.) · 2022Review
- High dose androgen suppresses natural killer cytotoxicity of castration-resistant prostate cancer cells via altering AR/circFKBP5/miRNA-513a-5p/PD-L1 signals.Cell death & disease · 2022Article
- When killers become thieves: Trogocytosed PD-1 inhibits NK cells in cancer.Science advances · 2022Article
- Natural killer cells and immune-checkpoint inhibitor therapy: Current knowledge and new challenges.Molecular therapy oncolytics · 2022Review
- Intravesical immunotherapy with a GM-CSF armed oncolytic vesicular stomatitis virus improves outcome in bladder cancer.Molecular therapy oncolytics · 2022Article
- Reduced frequency of cytotoxic CD56Cancer immunology, immunotherapy : CII · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Increasing evidence supports a role for innate immune effector cells in tumor surveillance. Natural killer (NK) cells and myeloid cells represent the two main subsets of innate immune cells possessing efficient but quite different tumor suppressive abilities. Here, we describe the germline-encoded NK cell receptors that play a role in suppressing tumor development and describe briefly the cellular pathways leading to the upregulation of their ligands in tumor cells. We also describe mechanisms underlying the elimination of tumor cells by macrophages and a recently characterized mechanism dedicated to sensing cytosolic DNA that is implicated in antitumor immune responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.